Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.
Bastien G, McAnulty C, Ledjiar O, Socias ME, Le Foll B, Lim R, Hassan AN, Brissette S, Marsan S, Talbot A, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Bastien G, et al. Among authors: brissette s. Can J Psychiatry. 2023 Aug;68(8):572-585. doi: 10.1177/07067437221145013. Epub 2022 Dec 14. Can J Psychiatry. 2023. PMID: 36519188 Free PMC article. Clinical Trial.
[Opioid use disorder in patients with chronic non-cancer pain].
Brabant M, Brissette S, Lauzon P, Marsan S, Ouellet-Plamondon C, Pelletier MC. Brabant M, et al. Among authors: brissette s. Sante Ment Que. 2014 Fall;39(2):117-32. Sante Ment Que. 2014. PMID: 25590547 Free article. French.
A pilot, open-label, 8-week study evaluating desvenlafaxine for treatment of major depression in methadone-maintained individuals with opioid use disorder.
El Hage C, Ghabrash MF, Dubreucq S, Brissette S, Lespérance F, Lespérance P, Ouellet-Plamondon C, Bruneau J, Jutras-Aswad D. El Hage C, et al. Among authors: brissette s. Int Clin Psychopharmacol. 2018 Sep;33(5):268-273. doi: 10.1097/YIC.0000000000000223. Int Clin Psychopharmacol. 2018. PMID: 29738425 Clinical Trial.
Preferences for research design and treatment of comorbid depression among patients with an opioid use disorder: A cross-sectional discrete choice experiment.
Bastien G, Del Grande C, Dyachenko A, Kaczorowski J, Pagé MG, Brissette S, Lespérance F, Dubreucq S, Hooley P, Jutras-Aswad D. Bastien G, et al. Among authors: brissette s. Drug Alcohol Depend. 2021 Sep 1;226:108857. doi: 10.1016/j.drugalcdep.2021.108857. Epub 2021 Jun 27. Drug Alcohol Depend. 2021. PMID: 34225223 Free article.
Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial.
Morissette F, Mongeau-Pérusse V, Rizkallah E, Thébault P, Lepage S, Brissette S, Bruneau J, Dubreucq S, Stip E, Cailhier JF, Jutras-Aswad D. Morissette F, et al. Among authors: brissette s. Neuropsychopharmacology. 2021 Nov;46(12):2101-2111. doi: 10.1038/s41386-021-01098-z. Epub 2021 Jul 30. Neuropsychopharmacology. 2021. PMID: 34331010 Free PMC article. Clinical Trial.
Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals With Cocaine Use Disorder: Exploratory Results From a Randomized Controlled Trial.
Mongeau-Pérusse V, Rizkallah E, Morissette F, Brissette S, Bruneau J, Dubreucq S, Gazil G, Trépanier A, Jutras-Aswad D. Mongeau-Pérusse V, et al. Among authors: brissette s. J Addict Med. 2022 Sep-Oct 01;16(5):521-526. doi: 10.1097/ADM.0000000000000959. Epub 2022 Feb 8. J Addict Med. 2022. PMID: 35135986 Clinical Trial.
Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial.
Rizkallah E, Mongeau-Pérusse V, Lamanuzzi L, Castenada-Ouellet S, Stip E, Juteau LC, Brissette S, Bruneau J, Dubreucq S, Jutras-Aswad D. Rizkallah E, et al. Among authors: brissette s. Pharmacol Biochem Behav. 2022 May;216:173376. doi: 10.1016/j.pbb.2022.173376. Epub 2022 Mar 31. Pharmacol Biochem Behav. 2022. PMID: 35367279 Free article. Clinical Trial.
Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D, Le Foll B, Ahamad K, Lim R, Bruneau J, Fischer B, Rehm J, Wild TC, Wood E, Brissette S, Gagnon L, Fikowski J, Ledjiar O, Masse B, Socias ME; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Jutras-Aswad D, et al. Among authors: brissette s. Am J Psychiatry. 2022 Oct;179(10):726-739. doi: 10.1176/appi.ajp.21090964. Epub 2022 Jun 15. Am J Psychiatry. 2022. PMID: 35702828 Clinical Trial.
59 results